PURPOSE: The aim of our study was to evaluate if therapeutic success in the first-line of anticancer treatments in patients with NSCLC may predict treatment success in the following lines. METHODS: We analyzed the data of patients with NSCLC stage III/IV from the TULUNG registry separately for chemotherapy, TKIs, ALK inhibitors, and immunotherapy in the first line during the years 2011-2019. "Succesful treatment " was defined as PFS ≥ 6 months, a "good responder " was a patient with ˃50% of "successful treatment " lines. Treatment responses were analyzed separately for each drug group. Descriptive statistics, Fisher exact test, Pearson Chi-Squared test, log-rank test, and univariate/multivariate logistic regression models were used. RESULTS: The first-line TKI therapy was successful in 66.2%, while good responders accounted for 50.7% of the cohort and their rates were similar for all types of TKIs. First-line platinum-based chemotherapy was successful in 43.1% and 48.6% for combinations with pemetrexed and bevacizumab, respectively. Good responders accounted for 29.5% and 25.9%, respectively. In the group of ALK inhibitors, we observed treatment success in 52.3% of cases, while alectinib showed the highest effectiveness (up to 70%). Good responders constituted 50% of the group. In the first-line immunotherapy group, survival benefit was observed in 52.3%, and good responders constituted 52.3% of the cohort. CONCLUSION: We concluded that the treatment success in first-line therapies in patients with NSCLC may predict survival benefits in the subsequent lines, particularly in EGFR- or ALK-positive disease and immunotherapy-treated patients.

2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Pneumology and Thoracic Surgery Bulovka Hospital Prague Czech Republic

Department of Pneumology University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Pneumology University Hospital Motol Prague Czech Republic

Department of Pneumology University Hospital Pilsen Pilsen Czech Republic

Department of Respiratory Diseases University Hospital Brno Jihlavska Street 20 625 00 Brno EU Czech Republic

Department of Respiratory Medicine Thomayer Hospital Prague Czech Republic

Department of Respiratory Medicine University Hospital Olomouc Olomouc Czech Republic

Faculty of Medicine Charles University Prague Hradec Kralove Czech Republic

Faculty of Medicine Charles University Prague Pilsen Czech Republic

Faculty of Medicine Masaryk University Brno Czech Republic

Faculty of Medicine Palacky University Olomouc Czech Republic

Institute of Biostatistics and Analyses Ltd Brno Czech Republic

International Clinical Research Center St Anne's University Hospital Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc24000464

003      

CZ-PrNML

005      

20240213093210.0

007      

ta

008      

240109s2023 gw f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s00432-023-05431-5 $2 doi

035    __

$a (PubMed)37768380

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a gw

100    1_

$a Bratova, Monika $u Department of Respiratory Diseases, University Hospital Brno, Jihlavska Street 20, 625 00, Brno, EU, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic

245    10

$a Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer / $c M. Bratova, J. Skrickova, M. Matusikova, K. Hrabcova, L. Havel, L. Koubkova, M. Hrnciarik, J. Krejci, O. Fischer, M. Svaton, K. Brat

520    9_

$a PURPOSE: The aim of our study was to evaluate if therapeutic success in the first-line of anticancer treatments in patients with NSCLC may predict treatment success in the following lines. METHODS: We analyzed the data of patients with NSCLC stage III/IV from the TULUNG registry separately for chemotherapy, TKIs, ALK inhibitors, and immunotherapy in the first line during the years 2011-2019. "Succesful treatment " was defined as PFS ≥ 6 months, a "good responder " was a patient with ˃50% of "successful treatment " lines. Treatment responses were analyzed separately for each drug group. Descriptive statistics, Fisher exact test, Pearson Chi-Squared test, log-rank test, and univariate/multivariate logistic regression models were used. RESULTS: The first-line TKI therapy was successful in 66.2%, while good responders accounted for 50.7% of the cohort and their rates were similar for all types of TKIs. First-line platinum-based chemotherapy was successful in 43.1% and 48.6% for combinations with pemetrexed and bevacizumab, respectively. Good responders accounted for 29.5% and 25.9%, respectively. In the group of ALK inhibitors, we observed treatment success in 52.3% of cases, while alectinib showed the highest effectiveness (up to 70%). Good responders constituted 50% of the group. In the first-line immunotherapy group, survival benefit was observed in 52.3%, and good responders constituted 52.3% of the cohort. CONCLUSION: We concluded that the treatment success in first-line therapies in patients with NSCLC may predict survival benefits in the subsequent lines, particularly in EGFR- or ALK-positive disease and immunotherapy-treated patients.

650    _2

$a lidé $7 D006801

650    12

$a nemalobuněčný karcinom plic $7 D002289

650    12

$a nádory plic $7 D008175

650    _2

$a pemetrexed $x terapeutické užití $7 D000068437

650    _2

$a bevacizumab $x terapeutické užití $7 D000068258

650    _2

$a inhibitory proteinkinas $x terapeutické užití $7 D047428

650    _2

$a erbB receptory $7 D066246

655    _2

$a časopisecké články $7 D016428

700    1_

$a Skrickova, Jana $u Department of Respiratory Diseases, University Hospital Brno, Jihlavska Street 20, 625 00, Brno, EU, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic

700    1_

$a Matusikova, Magda $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic

700    1_

$a Hrabcova, Karolina $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic

700    1_

$a Havel, Libor $u Department of Respiratory Medicine, Thomayer Hospital, Prague, Czech Republic

700    1_

$a Koubkova, Leona $u Department of Pneumology, University Hospital Motol, Prague, Czech Republic $u 2nd Faculty of Medicine, Charles University, Prague, Czech Republic

700    1_

$a Hrnciarik, Michal $u Department of Pneumology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Faculty of Medicine, Charles University in Prague, Hradec Kralove, Czech Republic

700    1_

$a Krejci, Jana $u Department of Pneumology and Thoracic Surgery, Bulovka Hospital, Prague, Czech Republic

700    1_

$a Fischer, Ondrej $u Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic $u Faculty of Medicine, Palacky University, Olomouc, Czech Republic

700    1_

$a Svaton, Martin $u Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic $u Faculty of Medicine, Charles University in Prague, Pilsen, Czech Republic

700    1_

$a Brat, Kristian $u Department of Respiratory Diseases, University Hospital Brno, Jihlavska Street 20, 625 00, Brno, EU, Czech Republic. brat.kristian@fnbrno.cz $u Faculty of Medicine, Masaryk University, Brno, Czech Republic. brat.kristian@fnbrno.cz $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic. brat.kristian@fnbrno.cz $1 https://orcid.org/000000031674228X

773    0_

$w MED00009972 $t Journal of cancer research and clinical oncology $x 1432-1335 $g Roč. 149, č. 19 (2023), s. 17123-17131

856    41

$u https://pubmed.ncbi.nlm.nih.gov/37768380 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240109 $b ABA008

991    __

$a 20240213093207 $b ABA008

999    __

$a ok $b bmc $g 2049243 $s 1210158

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 149 $c 19 $d 17123-17131 $e 20230928 $i 1432-1335 $m Journal of cancer research and clinical oncology $n J Cancer Res Clin Oncol $x MED00009972

LZP    __

$a Pubmed-20240109